Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice

HIV Clinical Trials

Volumn 2, Issue 6, 2001, Pages 474-476

  Yozviak, J L ^a   Doerfler, R E ^a   Woodward, W C ^a  

^a Bornemann Internal Medicine   (United States)

Author keywords

Antiretroviral therapy; Nevirapine; Nonnucleoside reverse transcriptase inhibitors (NNRTIs)

Indexed keywords

LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; VIRUS LOAD;

EID: 0035212001     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/T0RR-TGY0-8QWB-8YT2     Document Type: Article

References (9)

1. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
2. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
3. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
4. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial
5. 36-week results of a randomized, open, multicenter trial comparing Combivir (AZT/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients. (COMBINE study)
6. Factors predictive of durable HIV suppression in randomized double-blind trial with nevirapine (NVP), zidovudine (ZDV), and lamivudine (3TC) in treatment-naive (ARV-n) patients with advanced AIDS
7. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
8. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen
9. Nevirapine containing potent antiretroviral therapy results in an antiatherogenic plasma lipid profile: Results from the Atlantic study